Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Receivables (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Receivables data on record, last reported at $30.6 million in Q4 2025.

  • For Q4 2025, Receivables fell 5.37% year-over-year to $30.6 million; the TTM value through Dec 2025 reached $30.6 million, down 5.37%, while the annual FY2025 figure was $30.6 million, 5.37% down from the prior year.
  • Receivables reached $30.6 million in Q4 2025 per OCUL's latest filing, roughly flat from $30.8 million in the prior quarter.
  • Across five years, Receivables topped out at $32.4 million in Q4 2024 and bottomed at $13.6 million in Q1 2021.
  • Average Receivables over 5 years is $24.6 million, with a median of $24.4 million recorded in 2023.
  • Peak YoY movement for Receivables: surged 551.84% in 2021, then decreased 8.98% in 2023.
  • A 5-year view of Receivables shows it stood at $21.1 million in 2021, then grew by 0.9% to $21.3 million in 2022, then grew by 22.76% to $26.2 million in 2023, then grew by 23.72% to $32.4 million in 2024, then fell by 5.37% to $30.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $30.6 million in Q4 2025, $30.8 million in Q3 2025, and $30.4 million in Q2 2025.